CtBP1 interacts with ikaros and modulates pituitary tumor cell survival and response to hypoxia

Molecular Endocrinology

Volumn 26, Issue 3, 2012, Pages 447-457

  Dorman, Katie ^a   Shen, Zhongyi ^a   Yang, Caimei ^a   Ezzat, Shereen ^a   Asa, Sylvia L ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C TERMINAL BINDING PROTEIN 1; IKAROS TRANSCRIPTION FACTOR; LYSOPHOSPHATIDIC ACID; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACTH SECRETING CELL; APOPTOSIS; ARTICLE; CELL GROWTH; CELL SURVIVAL; CELLULAR DISTRIBUTION; DOWN REGULATION; GROWTH HORMONE SECRETING CELL; HUMAN; HUMAN CELL; HYPOPHYSIS TUMOR; HYPOXIA; IN VITRO STUDY; PRIORITY JOURNAL; PROLACTIN SECRETING CELL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; UPREGULATION;

ADENOMA; ALCOHOL OXIDOREDUCTASES; ANIMALS; APOPTOSIS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA-BINDING PROTEINS; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; IKAROS TRANSCRIPTION FACTOR; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; PHOSPHORIC DIESTER HYDROLASES; PITUITARY GLAND; PITUITARY NEOPLASMS; PROTEIN BINDING; PROTEIN ISOFORMS; RATS; RNA INTERFERENCE;

MAMMALIA;

EID: 84863158084     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2011-1095     Document Type: Article

References (36)

1. Ezzat S, Mader R, Yu S, Ning T, Poussier P, Asa SL 2005 Ikaros integrates endocrine and immune system development. J Clin Invest 115:1021-1029.
2. Ezzat S, Mader R, Fischer S, Yu S, Ackerley C, Asa SL 2006 An essential role for the hematopoietic transcription factor Ikaros in hypothalamic-pituitary-mediated somatic growth. Proc Natl Acad Sci USA 103:2214-2219.
3. Ezzat S, Yu S, Asa SL 2003 Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 5 fibroblast growth factor receptor-4 promoter. Am J Pathol 163:1177-1184.
4. Ezzat S, Zhu X, Loeper S, Fischer S, Asa SL 2006 Tumor-derived Ikaros 6 acetylates the Bcl-XL promoter to up-regulate a survival signal in pituitary cells. Mol Endocrinol 20:2976-2986.
5. Ezzat S, Yu S, Asa SL 2005 The zinc finger Ikaros transcription factor regulates pituitary growth hormone and prolactin gene expression through distinct effects on chromatin accessibility. Mol Endocrinol 19:1004-1011.
6. Loeper S, Asa SL, Ezzat S 2008 Ikaros modulates cholesterol uptake: a link between tumor suppression and differentiation. Cancer Res 68:3715-3723.
7. Koipally J, Renold A, Kim J, Georgopoulos K 1999 Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes. EMBO J 18:3090-3100.
8. Kim J, Sif S, Jones B, Jackson A, Koipally J, Heller E, Winandy S, Viel A, Sawyer A, Ikeda T, Kingston R, Georgopoulos K 1999 Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. Immunity 10:345-355.
9. Koipally J, Georgopoulos K 2000 Ikaros interactions with CtBP reveal a repression mechanism that is independent of histone deacetylase activity. J Biol Chem 275:19594-19602.
10. Zhang Q, Wang SY, Nottke AC, Rocheleau JV, Piston DW, Goodman RH 2006 Redox sensor CtBP mediates hypoxia-induced tumor cell migration. Proc Natl Acad Sci USA 103:9029-9033.
11. Mroz EA, Baird AH, Michaud WA, Rocco JW 2008 COOHterminal binding protein regulates expression of the p16INK4A tumor suppressor and senescence in primary human cells. Cancer Res 68:6049-6053.
12. Grooteclaes M, Deveraux Q, Hildebrand J, Zhang Q, Goodman RH, Frisch SM 2003 C-terminal-binding protein corepresses epithelial and proapoptotic gene expression programs. Proc Natl Acad Sci USA 100:4568-4573.
13. Hildebrand JD, Soriano P 2002 Overlapping and unique roles for C-terminal binding protein 1 (CtBP1) and CtBP2 during mouse development. Mol Cell Biol 22:5296-5307.
14. Asa SL 2011 Tumors of the pituitary gland. AFIP atlas to tumor pathology, series 4, fascicle 15. Washington, DC: American Registry of Pathology
15. Viacava P, Gasperi M, Acerbi G, Manetti L, Cecconi E, Bonadio AG, Naccarato AG, Acerbi F, Parenti G, Lupi I, Genovesi M, Martino E 2003 Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J Endocrinol Invest 26:23-28.
16. Hanafusa H, Torii S, Yasunaga T, Nishida E 2002 Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat Cell Biol 4:850-858.
17. Edwin F, Singh R, Endersby R, Baker SJ, Patel TB 2006 The tumor suppressor PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation. J Biol Chem 281:4816-4822.
18. Quinlan KG, Verger A, Kwok A, Lee SH, Perdomo J, Nardini M, Bolognesi M, Crossley M 2006 Role of the C-terminal binding protein PXDLS motif binding cleft in protein interactions and transcriptional repression. Mol Cell Biol 26:8202-8213.
19. Wang J, Scully K, Zhu X, Cai L, Zhang J, Prefontaine GG, Krones A, Ohgi KA, Zhu P, Garcia-Bassets I, Liu F, Taylor H, Lozach J, Jayes FL, Korach KS, Glass CK, Fu XD, Rosenfeld MG 2007 Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature 446:882-887.
20. Paliwal S, Kovi RC, Nath B, Chen YW, Lewis BC, Grossman SR 2007 The alternative reading frame tumor suppressor antagonizes hypoxia-induced cancer cell migration via interaction with the COOH-terminal binding protein corepressor. Cancer Res 67: 9322-9329.
21. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, Liotta LA 1992 Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 267:2524-2529.
22. Yuelling LM, Fuss B 2008 Autotaxin (ATX): a multi-functional and multi-modular protein possessing enzymatic lysoPLD activity and matricellular properties. Biochim Biophys Acta 1781:525-530.
23. Moolenaar WH, Kranenburg O, Postma FR, Zondag GC 1997 Lysophosphatidic acid: G-protein signalling and cellular responses. Curr Opin Cell Biol 9:168-173.
24. Kwon YJ, Sun Y, Kim NH, Huh SO 2009 Phosphorylation of CREB, a cyclic AMP responsive element binding protein, contributes partially to lysophosphatidic acid-induced fibroblast cell proliferation. Biochem Biophys Res Commun 380:655-659.
25. Struthers RS, Vale WW, Arias C, Sawchenko PE, Montminy MR 1991 Somatotroph hypoplasia and dwarfism in transgenic mice expressing a non-phosphorylatable CREB mutant. Nature 350: 622-624.
26. Asa SL, Ezzat S 2009 The pathogenesis of pituitary tumors. Annu Rev Pathol 4:97-126.
27. Srikant CB 1997 Human somatostatin receptor mediated antiproliferative action evokes subtype selective cytotoxic and cytostatic signaling. Yale J Biol Med 70:541-548.
28. Baumeister H, Wegner M, Richter D, MeyerhofW2000 Dual regulation of somatostatin receptor subtype 1 gene expression by pit-1 in anterior pituitary GH3 cells. Mol Endocrinol 14:255-271.
29. Yigzaw Y, Cartin L, Pierre S, Scholich K, Patel TB 2001 The C terminus of sprouty is important for modulation of cellular migration and proliferation. J Biol Chem 276:22742-22747.
30. Lee CC, Putnam AJ, Miranti CK, Gustafson M, Wang LM, Vande Woude GF, Gao CF 2004 Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene 23:5193-5202.
31. Höckel M, Vaupel P 2001 Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276.
32. Kontogeorgos G, Sambaziotis D, Piaditis G, Karameris A 1997 Apoptosis in human pituitary adenomas: a morphologic and in situ end-labeling study. Mod Pathol 10:921-926.
33. Kulig E, Jin L, Qian X, Horvath E, Kovacs K, Stefaneanu L, Scheithauer BW, Lloyd RV 1999 Apoptosis in nontumorous and neoplastic human pituitaries: expression of the Bcl-2 family of proteins. Am J Pathol 154:767-774.
34. Kapranos N, Kontogeorgos G, Horvath E, Kovacs K 2004 Morphology, molecular regulation and significance of apoptosis in pituitary adenomas. Front Horm Res 32:217-234.
35. Schaeper U, Boyd JM, Verma S, Uhlmann E, Subramanian T, Chinnadurai G 1995 Molecular cloning and characterization of a cellular phosphoprotein that interacts with a conserved C-terminal domain of adenovirus E1A involved in negative modulation of oncogenic transformation. Proc Natl Acad Sci USA 92: 10467-10471.
36. +-regulated dehydrogenase. Mol Cell 10:857-869